New Zealand markets closed

NXTC Sep 2024 2.500 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
1.25000.0000 (0.00%)
At close: 03:56PM EDT
Full screen
Previous close1.2500
Open1.2500
Bid0.0000
Ask1.3500
Strike2.50
Expiry date2024-09-20
Day's range1.2500 - 1.2500
Contract rangeN/A
Volume1
Open interest53
  • GlobeNewswire

    NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024

    Of the evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 2 confirmed ongoing PRs and a disease control rate of 51%Of the 7 evaluable ovarian cancer patients, there were 3 PRs and a disease control rate of 43%Data to be presented June 1, 2024, 9:00 am-12:00 pm CT BELTSVILLE, Md., May 30, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class the

  • GlobeNewswire

    NextCure Provides Business Update and Reports First Quarter 2024 Financial Results

    Phase 1b data for NC410 combo with pembro to be presented at ASCO annual meeting on June 1Presented preclinical data from LNCB74 (B7-H4 ADC) at recent AACR annual meeting Cash of approximately $96.0 million expected to fund operations into second half of 2026 BELTSVILLE, Md., May 02, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today pr

  • GlobeNewswire

    NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024

    BELTSVILLE, Md., April 24, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that clinical trial investigator Eric S. Christenson, M.D., Assistant Professor of Oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, will present a poster on clinical data from the Phase 1b portion of a study evaluating NC410 in com